Potential biomarkers for predicting the efficacy of a pembrolizumab-containing regimen in advanced cervical cancer: A real-world analysis
CPS and TPS showed a modest correlation with progression-free survival and NLR prior to immunotherapy demonstrated the best treatment efficacy for advanced cervical cancer.
Authors
- Shintaro Yanazume (ORCID: https://orcid.org/0000-0003-2297-6648)
- Shinichi Togami (ORCID: https://orcid.org/0000-0003-1920-9405)
- Akihide Tanimoto (ORCID: https://orcid.org/0000-0001-7508-1624)
- Ikumi Kitazono (ORCID: https://orcid.org/0000-0002-6746-6695)
- Hiroaki Kobayashi (ORCID: https://orcid.org/0000-0003-2491-2189)
Institutions
- Kagoshima University (JP)
- Kagoshima University Hospital (JP)
Publication Details
- Journal
- Journal of Turkish Society of Obstetric and Gynecology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.4274/tjod.galenos.2025.93607
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00